Separating benign from atypical epithelial proliferation and ductal verus lobular in situ lesions in breast can sometimes be challenging by morphology alone due to high interobserver variability. The purpose of this study is analyze the utilities of estrogen receptor (ER), cytokeratin 5/6 (CK5/6), and cytokeratin 903 (CK903) as a single immunostain or as combined biomarkers to differentiate flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) from usual ductal hyperplasia (UDH), and DCIS from lobular carcinoma in situ (LCIS). Methods: Morphological examinations of breast lesions were performed by three pathologists with concordance. A total of 20 UDH, 10 FEA, 20 ADH, 20 low-grade DCIS, and 20 LCIS cases from different patients separately were stained with ER, CK5/6, and CK903. LCIS included cases with pleomorphic features. Most were also stained with progesterone receptor (PR), p63, and smooth muscle myosin heavy chain (SMMHC). Nuclear stainings of ER and PR, and cytoplasmic stainings of CK5/6 and CK903 were scored as diffuse, focal, or negative. Results: For ER, 93% of FEA, ADH, DCIS, and LCIS had diffuse stainings, whereas UDH only showed focal or negative stainings. For CK5/6, 94% of FEA, ADH, DCIS, and LCIS revealed negative stainings, but all of the UDH demonstrated diffuse stainings. For CK903, 90% of FEA, ADH, and DCIS were negative to focally positive, and all of the UDH and 90% of LCIS were diffusely positive. Combining ER, CK5/6, and CK903 increased sensitivity and specificity of the diagnoses of these lesions. PR, p63, and SMMHC did not show statistically significant differences between these entities. However, p63 and SMMHC exhibited diminished expression in DCIS and LCIS compared to UDH. Conclusion: In morphologically controversial cases, combining ER, CK5/6, and CK903 markers is helpful in differentiating UDH from FEA and ADH, and DCIS from LCIS.
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